Insights

Early Phase Opportunity ReNetX Bio is approaching Phase 2 of testing for AXER-204, indicating a near-term need for CROs, clinical trial support, and regulatory consulting services to accelerate trials and prepare for potential partnerships.

CNS Focus Specialization in central nervous system injuries such as spinal cord injury, glaucoma, and traumatic brain injury positions the company for partnerships with researchers, philanthropic funders, and niche CROs serving neurology, ophthalmology, and neurorehabilitation markets.

Strategic Leadership CEO Erika Smith and a growing scientific advisory board suggest opportunities for advisory roles, sponsorships, and collaboration discussions with academic institutions and biotech networks seeking leadership in translational neuroscience.

Funding & Growth With modest revenues and $9.8M in funding, there is potential for grant collaborations, co-development deals, and early-stage licensing conversations with biotech investors and larger partners looking to expand CNS portfolios.

Tech & Analytics Current tech stack including analytics and web tools signals readiness for digital outreach, partner discovery, and data-driven marketing programs to engage clinical researchers, trial sites, and industry stakeholders.

Similar companies to ReNetX Bio

ReNetX Bio Tech Stack

ReNetX Bio uses 8 technology products and services including Snowplow, Weebly, Google Workspace, and more. Explore ReNetX Bio's tech stack below.

  • Analytics
  • Content Management System
  • jQuery
    Javascript Libraries
  • Cloudflare Bot Management
    Security
  • MediaElement.js
    Video Players
  • Google Analytics
    Web Analytics
  • Google Search Console
    Web Analytics

ReNetX Bio's Email Address Formats

ReNetX Bio uses at least 1 email format:
ReNetX Bio Email FormatsExamplePercentage
FLast@renetx.comJDoe@renetx.com
100%

Frequently Asked Questions

What is ReNetX Bio's official website and social media links?

Minus sign iconPlus sign icon
ReNetX Bio's official website is renetx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does ReNetX Bio generate?

Minus sign iconPlus sign icon
As of October 2026, ReNetX Bio's annual revenue is estimated to be <$1M.

What is ReNetX Bio's SIC code and NAICS code?

Minus sign iconPlus sign icon
ReNetX Bio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ReNetX Bio have currently?

Minus sign iconPlus sign icon
As of October 2026, ReNetX Bio has approximately 2 employees across 1 continents, including North America. Key team members include Chief Executive Officer: E. A. Explore ReNetX Bio's employee directory with LeadIQ.

What industry does ReNetX Bio belong to?

Minus sign iconPlus sign icon
ReNetX Bio operates in the Biotechnology Research industry.

What technology does ReNetX Bio use?

Minus sign iconPlus sign icon
ReNetX Bio's tech stack includes Snowplow, Weebly, Google Workspace, jQuery, Cloudflare Bot Management, MediaElement.js, Google Analytics and Google Search Console.

What is ReNetX Bio's email format?

Minus sign iconPlus sign icon
ReNetX Bio's email format typically follows the pattern of FLast@renetx.com. Find more ReNetX Bio email formats with LeadIQ.

How much funding has ReNetX Bio raised to date?

Minus sign iconPlus sign icon
As of October 2026, ReNetX Bio has raised $9.8M in funding. The last funding round occurred on Oct 28, 2020 for $2.8M.
ReNetX Bio logo

ReNetX Bio

Biotechnology ResearchConnecticut, United States2-10 Employees

ReNetX Bio is a small biotechnology company based in New Haven, Connecticut, focused on developing therapies for injuries and damage to the central nervous system. Its flagship program, AXER-204, aims to restore neural connectivity after injury by inhibiting receptors that suppress axon regrowth, with the company progressing toward Phase 2 testing. The work targets conditions such as spinal cord injury, glaucoma, and traumatic brain injury, addressing unmet needs in CNS repair.

Its customer frame includes clinicians and researchers seeking new CNS injury treatments for patients, and the company operates within the biotechnology research industry to deliver first-in-class therapeutics. A notable 2020 development was expanding its Scientific Advisory Board with Dr. Kevin Malobisky, reflecting ongoing scientific collaboration.

Section iconCompany Overview

Website
renetx.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
2-10

Section iconFunding & Financials

  • $9.8M

    ReNetX Bio has raised a total of $9.8M of funding over 3 rounds. Their latest funding round was raised on Oct 28, 2020 in the amount of $2.8M as a Venture Round.

  • <$1M

    ReNetX Bio's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.